| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d4dc42489d4d5995ea72c0615204738c |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0638
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2500-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5158
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5156
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2818
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0011
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39541 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0783
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| filingDate |
2021-08-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7e462bb07c17d7ac21a527d3876478f1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b6cee205a4adc2fdccdedd90d5db1bc0 |
| publicationDate |
2022-02-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2022038157-A1 |
| titleOfInvention |
Lfa-1 signalling mediator for use in cancer therapy |
| abstract |
The present invention relates to an LFA-1 signalling mediator with moderate LFA-1 stabilization properties for use in cancer immunotherapy or a composition for use in cancer immunotherapy comprising an immune system modulator, wherein the immune system modulator enhances the immune response against cancer, and an LFA-1 signalling mediator with moderate LFA-1 stabilization properties wherein the LFA-1 signalling mediator selectively and significantly enhances the anti-cancer immune response. The composition may comprise a carrier for target delivery of the composition. |
| priorityDate |
2020-08-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |